Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the methacholine PC20 of two different modern-delivery aerosol systems to determine if one may replace the other for use in clinical settings.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McMaster University
• Treatments: Methacholine Chloride

Criteria

Inclusion Criteria:

• Subjects with stable asthma.

• Tidal breathing PC20≤16 mg/mL.

• Baseline FEV1 more than 65% of predicted normal.

• Able to complete 3 methacholine challenges on 3 separate days at the same time of day, at least 24-hours apart and within a 2-week period. (1 during screening and the other 2 during the study)

Exclusion Criteria:

• Airway infection or allergen exposure during the last 4 weeks.

• Exacerbation during the last 4 weeks.

• Change in dosage of inhaled or oral steroids during the last 4 weeks.

• Inhaled salbutamol less than 8 hours prior to testing.

• Inhaled formoterol or salmeterol less than 36 hours prior to testing.

• Antihistamines during the last 48 hours.

• Chronic health conditions that are determined by the principal investigator to be significant (eg cystic fibrosis).

• Smokers

• Pregnant women.